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Fig. 1 Western blot tests the CSA and CSB knockout cell candidates. We achieved a 33% and 38% knockout efficiency for CSA
and CSB, respectively. We used RPA1 as a loading control for both protein blots, with a weight of 70 kDa. CSA appeared at 46
kDa, while CSB appeared at 168 kDa. The clone number of each single cell clone tested for knockout validation is shown above
the blots. The first lane in each blot is a wild type (WT) positive control.

Materials & Methods
293A cell transient transfection using Mirus LT1 transfection
reagent. Puromycin selection 2 days later.

Single cell clone formation
using a 96 well plate.

Western blot analysis to test
gRNA knockout efficiency.

2 Week Incubation
Plasmid DNA ligation
and Sanger
sequencing to confirm
single clone knockout.

Western blot analysis
to confirm single clone
knockout.

Culture single cell clone knockouts until there are an adequate number for
LD20 screen seeding at 5 million cells per replicate per treatment.
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v A CRISPR/Cas9 full genome synthetic lethality screen on CSA-/- and CSB-/- cells
can be used to identify DDR pathways that replace deficient TC-NER in humans.
v We plan to use the chemotherapeutic drug Illudin-S, whose clinical use is limited
due to high toxicity, in synthetic lethality screening to cause DNA lesions repaired
almost exclusively by TC-NER.3
v To use Illudin-S, we must determine the drug doses ideal for maintaining 400
times coverage of the CRISPR gRNA library through the screen while displaying
sufficient cellular toxicity to cause a 20% cell reduction (LD20) at each timepoint.4
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v Transcription-Coupled Nucleotide Excision Repair (TC-NER) is a subpathway of
nucleotide excision repair that repairs DNA lesions on actively transcribed genes.
v When TC-NER fails as occurs in Cockayne Syndrome (CS), it is unknown what
repair mechanisms assume the responsibility of DNA damage repair (DDR).
v CS patients experience UV sensitivity, premature aging, neurodegeneration, and
dwarfism.1
v CS patients have deficiencies in TC-NER-specific proteins Cockayne Syndrome
type A (CSA) and Cockayne Syndrome Type B (CSB).1,2
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Fig. 2A-C To calculate percent survival, we divided the cell count for each Illudin-S concentration by the 0 μg/mL control cell
count at every passage. We conducted this calculation separately for both technical replicates and averaged them. The error bars
show variation in replicate measurements. The targeted 80% cell survival is denoted by the blue dotted line for the LD20 screen
data within each knockout cell type. A) proves that 20% lethality for WT cells was consistent at each passage for the 1.0 μg/mL
concentration within cell survival fluctuations. This concentration is thus a possible candidate for future 293A WT screens. WT
cells did not suffer extensive cumulative genotoxic effects as expected since they possess an efficient TC-NER pathway.
B) shows that by the screen’s end, the 0.5 μg/mL dose achieves 20% lethality for CSB-/- cells, making it an LD20 candidate in
future screens. Because they are TC-NER deficient, CSB-/- cells experience heightened cumulative genotoxic effects at higher
Illudin-S doses in comparison to WT cells. C) exhibits the considerably higher sensitivity to Illudin-S that CSA-/- cells demonstrate
in comparison to WT or CSB-/-. All concentrations caused excessive cell death, making none LD20 candidates. All concentrations
other than the lowest 0.5 μg/mL dose resulted in less than 5 million cells prior to the screen’s conclusion.
v The heightened sensitivity of CSA-/- cells to Illudin-S is unexpected due to the more central role of CSB in the TC-NER
pathway. We double checked the validity of the cell knockouts with Western blotting, which confirmed our results. Further
drug screens are necessary to validate the heightened sensitivity of CSA-/- to Illudin-S as observed in this study.

Conclusions & Future Directions
v Lower Illudin-S doses are most suitable to maintain adequate gRNA library coverage in 293A full genome CRISPR synthetic
lethality screens. Especially for TC-NER deficient cells, we will execute further Illudin-S drug screening at lower drug
concentrations to identify LD20 concentrations for 293A CRISPR screens, using this screen’s lowest 0.5 μg/mL concentration
as the highest concentration tested.
Following confirmation of proper Illudin-S doses for the 293A cell line, we will conduct LD20 screens on other cell lines such as
the HCT116 colon cancer cell line to prepare for CRISPR synthetic lethality screens using other cell types.

2.0 μg/mL

Validated Knockout Cells
LD20 Screen
v 5 million cells were seeded to ten 150 mm plates. Two technical replicates were
used, each with a 0, 0.5, 1.0, 1.5, and 2.0 μg/mL Illudin-S concentration.2
v Cells were cultured in 25 mL DMEM with bovine serum.
v Cells were passaged, counted, and reseeded at 5 million cells per dish every
three days for 18 days.
v Cells of each dose had the assigned dose readministered every reseeding.
v When a cell count dropped below 5 million, data was cut off for that treatment
since the next passage could not be adequately seeded to maintain an equal
number of cells between treatment groups.
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